Want to see GB:CIZ full AI Analyst Report?
Top Page
Cizzle Biotechnology Holdings PLC
(LSE:CIZ)
Select Model
Select Model
Rating:43Neutral
Price Target:
1.00 p
▼(-33.33% Downside)
Action:Reiterated
Date:10/16/26
The score is driven primarily by weak financial performance, including ongoing losses, consistent cash burn, and a materially deteriorated balance sheet with equity turning negative. Technical indicators add pressure with a clear downtrend and negative momentum, despite near-oversold readings. Valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Focused diagnostic opportunity
The company is concentrated on a defined diagnostic application with potentially meaningful clinical value: earlier lung-cancer detection. A focused biomarker-based platform can support differentiated product development and create a clear pathway toward validation, regulatory progress, and eventual commercialization.
Negative Factors
Pre-commercial revenue position
The absence of reported revenue indicates that the business has not yet demonstrated commercial adoption or recurring income from its diagnostic technology. Until validation, regulatory progress, and market launch translate into sales or licensing receipts, financial performance remains dependent on external funding and future execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused diagnostic opportunity
The company is concentrated on a defined diagnostic application with potentially meaningful clinical value: earlier lung-cancer detection. A focused biomarker-based platform can support differentiated product development and create a clear pathway toward validation, regulatory progress, and eventual commercialization.
Read all positive factors
Cizzle Biotechnology Holdings PLC (CIZ) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.28M
Dividend YieldN/A
Average Volume (3M)1.30M
Price to Earnings (P/E)―
Beta (1Y)-0.91
Revenue GrowthN/A
EPS Growth42.86%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume1,097,003
30 Day Avg. Volume1,295,385
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model
Company Description
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzl...
How the Company Makes Money
Cizzle Biotechnology’s primary intended revenue model is to generate income from the commercialization of its lung-cancer diagnostic technology, typically through licensing and/or partnership arrangements with established diagnostics, laboratory, ...
Cizzle Biotechnology Holdings PLC Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -724.00K | -753.00K | 2.00 | 0.00 | -962.04K | -3.96M |
| Net Income | -652.00K | -691.00K | -2.17K | -1.72K | -910.00K | -3.92M |
Balance Sheet | ||||||
| Total Assets | 191.00K | 245.00K | 492.00K | 1.69M | 2.79M | 1.16M |
| Cash, Cash Equivalents and Short-Term Investments | 81.00K | 116.00K | 387.00K | 1.56M | 478.00K | 875.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 528.00K | 585.00K | 410.00K | 186.00K | 145.00K | 218.00K |
| Stockholders Equity | -337.00K | -340.00K | 82.00K | 1.51M | 2.64M | 937.00K |
Cash Flow | ||||||
| Free Cash Flow | -532.00K | -498.00K | -358.00K | -639.00K | -872.00K | -1.21M |
| Operating Cash Flow | -532.00K | -496.00K | -358.00K | -639.00K | -872.00K | -1.01M |
| Investing Cash Flow | 0.00 | -2.00K | 0.00 | 0.00 | -120.00K | -154.00K |
| Financing Cash Flow | 431.00K | 249.00K | 579.00K | 305.00K | 595.00K | 2.03M |
Cizzle Biotechnology Holdings PLC Technical Analysis
Negative
1.50
Price Trends
1.41
Negative
1.79
Negative
1.96
Negative
Market Momentum
-0.11
Negative
30.92
Neutral
76.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CIZ, the sentiment is Negative. The current price of 1.5 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.41, and below the 200-day MA of 1.96, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 30.92 is Neutral, neither overbought nor oversold. The STOCH value of 76.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CIZ.
Cizzle Biotechnology Holdings PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £5.99M | -1.40 | -77.85% | ― | 11.90% | -2864.29% | |
46 Neutral | £2.24M | -0.89 | -71.49% | ― | -34.36% | 57.45% | |
43 Neutral | £5.28M | -6.88 | 192.61% | ― | ― | 42.86% | |
43 Neutral | £2.74M | -2.23 | -83.53% | ― | ― | 93.02% | |
42 Neutral | £4.64M | -1.70 | -93.92% | ― | ― | 55.56% | |
42 Neutral | £2.59M | -0.28 | -152.41% | ― | -70.77% | 60.39% |
* Healthcare Sector Average
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.10
-0.60
-35.29%
GB:TCF
Evgen Pharma
0.17
-0.04
-19.05%
GB:FUM
Futura Medical
0.18
-2.43
-93.27%
GB:NFX
Nuformix Plc
0.11
-0.38
-78.35%
GB:OPTI
OptiBiotix Health
5.80
-2.20
-27.50%
GB:VAL
ValiRx plc
0.17
-0.07
-30.61%
Cizzle Biotechnology Holdings PLC Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cizzle Biotechnology Gains Industry Recognition for Early Lung Cancer Test
Positive
Oct 19, 2026
Cizzle Biotechnology Holdings PLC, a UK-based developer of blood-based diagnostics for early cancer detection, is advancing commercialisation of its CIZ1B biomarker test for early-stage lung cancer. The test, built on research into the CIZ1 protei...
Business Operations and StrategyProduct-Related Announcements
Cizzle Biotechnology Restructures U.S. Royalty Deal as Lung Cancer Test Rollout Accelerates
Positive
Oct 15, 2026
Cizzle Biotechnology has validated its CIZ1B lung cancer biomarker test in a CLIA-accredited U.S. laboratory and is expanding access through additional partners such as BioBridge Global to build a resilient national testing network. The company su...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Cizzle Biotechnology Enters Commercial Phase as U.S. Lung Cancer Test Wins CLIA Approval
Positive
Sep 30, 2026
Cizzle Biotechnology has transitioned from development to commercialisation after its CIZ1B biomarker blood test for early-stage lung cancer gained CLIA accreditation for clinical use in the U.S., unlocking access to the world’s largest diag...
Business Operations and StrategyProduct-Related Announcements
Cizzle expands U.S. lung cancer test access with new BioBridge lab deal
Positive
Aug 3, 2026
Cizzle Biotechnology’s North American licensee, Cizzle Bio Inc, has signed a strategic laboratory agreement with BioBridge Global’s BBG Advanced Therapies to offer the CIZ1B biomarker blood test for lung cancer through a CLIA-certified...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.